NIDA Is Betting $12.6 Million That Addiction Can't Be Studied One Drug at a Time

The sentence Olivier George uses to explain his new center is not about biology. It is about the shape of the research field itself.

"Addiction research has traditionally been divided into separate areas — alcohol research on one side and drug research on the other," said George, a professor of psychiatry at the UC San Diego School of Medicine. "But that division doesn't reflect how addiction occurs in the real world. People often use more than one substance, so we need to understand what these substances have in common, as well as what makes them different."

On Sept. 30, UC San Diego announced that George will direct a new center built on that complaint. The National Institute on Drug Abuse is putting $12.6 million behind it over five years, and the institution is calling it the Polysubstance Addiction Research Center — PARC, for short.

A Field Organized Around Single Molecules

The gap George describes is real and old. Federal surveillance paints a drug supply in which combinations are ordinary: fentanyl pressed into counterfeit pills alongside methamphetamine, cocaine cut with veterinary sedatives, alcohol present in a large share of fatal polysubstance overdoses. Laboratory science has been slower to follow. A grant application is usually written around one compound, one receptor, one behavioral paradigm, because that is what a single laboratory can control.

The consequence is a literature that describes parts while patients arrive whole. Emergency department toxicology panels routinely return three and four substances at once, and treatment intake forms still ask for a single "drug of choice" — a question a large share of people in treatment cannot honestly answer. Researchers have said so for years in the limitations sections of their own papers. Funding structures rarely reward doing anything about it.

PARC's response is not to add another compound but to compare them under one roof. The center will run coordinated studies of cocaine, oxycodone, alcohol, and the specific pairing of cocaine with oxycodone — a combination that shows up in toxicology reports but rarely in controlled animal research designs.

It will pull together psychiatry, medicine, obstetrics, gynecology and reproductive sciences, computational biology and bioinformatics, and the Veterans Affairs San Diego Healthcare System. Barbara Jung, associate vice chancellor and dean of the UC San Diego School of Medicine, framed the award as a recognition of "his vision for bringing together researchers across disciplines to address the complexities of addiction."

What the Center Will Actually Measure

Rather than chasing a single biomarker, PARC is organized around what it calls the "One-Individual Multiscale Atlas" — a data structure meant to connect layers that are normally published in separate papers. Genes and individual cells on one end; brain circuits and peripheral organs in the middle; observable behavior at the other. Findings from animal models are then to be compared against human genetic, brain imaging and other biological datasets to see whether a change at one level tracks a change at another.

Three projects, one atlas

The work is split into three interconnected projects. One examines brain connectomics — how addiction reorganizes the way brain networks communicate. A second, brain transcriptomics, tracks changes in gene activity within specific types of brain cells. The third, gut-vagus multiomics, asks how the gut and the vagus nerve, which links the brain to organs throughout the body, may shape addiction-related behavior.

That last project is where the center is furthest from conventional addiction science. The gut-brain axis has moved quickly from curiosity to serious hypothesis over the past several years, and PARC is staking part of a five-year budget on the claim that it belongs in the same conversation as dopamine and the prefrontal cortex.

Abraham Palmer, professor and vice chair of basic research in the psychiatry department, described the strategy as an attempt to use "cutting-edge techniques to understand how these individual differences shape addiction risk at the molecular, cellular and brain circuit levels." The word doing the work there is individual. Much of what patients experience as a coin flip — why one person who uses opioids for a month walks away and another does not — is variation the field has documented far more often than it has explained.

From Statistical Association to Intervention

The center's second aim is the one that separates a research program from a data-mining exercise. Having identified biological differences associated with heavy use, PARC intends to test whether altering those processes actually changes behavior, using medications and other interventions against pathways involved in cellular stress, immune signaling and gut-brain communication.

"We want to go one step further than simply finding a biological difference associated with addiction," George said. "We want to test whether changing that biological process changes addiction-related behavior. That could help us identify targets that are more likely to translate into new treatments."

It is worth being precise about how far that is from a prescription. Testing a target in a controlled model is the beginning of a translational pipeline, not the end of one, and the interventions under discussion sit behind years of safety work, dosing studies and human trials. For readers looking for what medication-assisted treatment looks like today, the answer is buprenorphine, methadone, naltrexone and the counseling that surrounds them — none of which will be replaced by anything announced this week.

The Hard Part Is the Comparison

Building the atlas is the easier half. The harder half is making its layers commensurable — genes, cells, circuits, organs and behavior are recorded on different timescales with different statistical properties, and the machine-learning methods meant to bridge them can find patterns in noise as readily as signal. The center's plan to check model findings against human genetic and imaging datasets is the main defense against that, and also the point where sample sizes and effect sizes tend to get small. It is the part of the program most likely to produce either a genuinely new hypothesis or a decade of inconclusive replication.

An Asset That Already Exists

The third aim is infrastructure, and it is the least glamorous and possibly the most consequential. PARC will expand an addiction biobank that already holds more than 40,000 specimens collected from studies involving cocaine, oxycodone and alcohol. That collection has supported 75 external research projects to date, according to the university.

Alongside the specimens, the center will distribute standardized behavioral models, computational tools and shared datasets, with data deposited in National Institutes of Health repositories so outside teams can reproduce results. The center's stated ambition is to become a national resource rather than a campus one.

The foundation is not new. UC San Diego addiction researchers have worked together for six years across more than a dozen laboratories, producing hundreds of publications and shared tools. The NIDA award formalizes that arrangement and pays for it.

What the Award Does Not Settle

Four caveats are worth holding onto.

The first is duration. A five-year award funds a start, not a conclusion; centers of this kind are usually judged on what they publish in years three through five and on whether they survive a competitive renewal. The second is translation. Nothing in the announcement claims a new therapy, and the history of addiction neuroscience is littered with promising animal-model targets that did not survive human trials.

The third is scale. Twelve and a half million dollars over five years is a substantial basic-science award and a rounding error against the cost of the crisis it addresses; NIDA's annual budget runs into the billions, and most of it flows to individual investigator grants. What PARC is being asked to prove, in part, is that coordination produces findings that separate laboratories working alone cannot.

The fourth is scope. Cocaine, oxycodone and alcohol are the center's focus. They are not the whole of the current overdose crisis, which in recent years has been driven by illicitly manufactured fentanyl and, increasingly, by novel synthetic opioids and adulterants that often arrive in combination. A center built to study polysubstance use will have to decide how quickly it can absorb substances it did not start with.

That is a limitation of resources and time rather than of design. And the design is, at minimum, an admission of something the treatment field has argued for years: patients rarely arrive with a single tidy diagnosis, and research that insists on one may be studying a population that does not exist.

For families and clinicians working with stimulant addiction alongside opioid use — the fastest-growing polysubstance pattern in the country — the practical question is whether a coordinated research program shortens the distance to better care. The honest answer is that it might, eventually, and that "eventually" is doing a great deal of work in that sentence.

What PARC does offer now is a clearer target. Not a molecule. A method.